CUDC-907 boosts temozolomide response in glioblastoma by dual PI3K/HDAC inhibition
Glioblastoma (GBM) is an aggressive brain cancer that frequently returns after treatment, largely due to acquired resistance to standard chemotherapy ...
Glioblastoma (GBM) is an aggressive brain cancer that frequently returns after treatment, largely due to acquired resistance to standard chemotherapy ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine